PDM-02 - (Sponsored Lunch Presentation) Dual NMR Agonists to overcome the Current Shortfalls in the Management of Severe Acute Pain: Break the Mold in Pain Biology

Moderate to severe acute pain is a prevalent condition, posing significant challenges with management. Opioids are often the only effective treatment, forcing clinicians and patients to choose between undertreatment or opioid use, each carrying inherent risks.

The development of dual NMR agonists that simultaneously activate the nociceptin/orphanin FQ (NOP) receptor and the MOP receptor, represents a promising new class of drugs with the potential of inducing potent analgesia with less side effects. The activation of the NOP receptor is crucial in inducing pain relief and, more importantly, counteracts important adverse effects associated with MOP activation such as respiratory depression, euphoria, and dependence. Clinical data are beginning to confirm the potential of this novel mechanism.

Join us as we explore clinical evidence supporting the safety and efficacy of dual-[JP2] NMR agonists in the treatment of moderate to severe acute pain with limited risk and consider how this novel mechanism could reshape the future of pain management.

Lunch will be provided, and seating is first come, first serve.

This lunch is sponsored by Tris Pharma. This session is not eligible for credit.